Bio Medica Laboratories Limited officially opened its SME Initial Public Offering (IPO) for public subscription on May 20, 2026. The IPO will remain open until May 22 and is proposed to be listed on the NSE SME platform later this month. The pharmaceutical company plans to raise approximately ₹18.75 crore through a fresh issue of equity shares.
The IPO price band has been fixed between ₹72 and ₹76 per equity share, while retail investors are required to apply for a minimum lot size of 1,600 shares. According to market analysts, the issue has generated healthy interest among SME investors because of the company’s presence in the pharmaceutical formulations and healthcare manufacturing segment.
Bio Medica Laboratories is engaged in the manufacturing and marketing of pharmaceutical formulations, including tablets, capsules, syrups, injectables, and healthcare products. The company supplies products across domestic markets and also caters to institutional and contract manufacturing clients. Industry experts noted that increasing demand for affordable healthcare products and expansion of India’s pharmaceutical sector have created growth opportunities for medium-sized pharma manufacturers.
The company reportedly operates manufacturing facilities compliant with industry quality standards and has been expanding its product portfolio over the last few years. Market observers believe that growing penetration into tier-2 and tier-3 healthcare markets could support future revenue growth for the company. Analysts also highlighted that India’s pharmaceutical sector continues to attract investor interest due to strong export demand and domestic healthcare expansion.
According to the company’s IPO documents, the proceeds from the issue will primarily be utilized for working capital requirements, upgrading manufacturing infrastructure, repayment of certain borrowings, and general corporate purposes. Experts believe investment into production capacity and operational modernization may improve manufacturing efficiency and strengthen the company’s long-term growth prospects.
Financially, Bio Medica Laboratories has shown steady business growth in recent years. The company reported improvement in revenue and profitability for FY2025 compared to previous financial years. Analysts stated that healthy EBITDA margins and improving operational performance have contributed to positive investor sentiment around the issue.
Grey market activity for the IPO has remained moderately positive ahead of subscription closing. Latest market tracking reports indicate that the Grey Market Premium (GMP) is trading around ₹8–₹10 per share, suggesting expectations of moderate listing gains if subscription demand remains strong during the final bidding sessions.
Industry experts have also highlighted certain business risks associated with the company. Competition from larger pharmaceutical companies, regulatory compliance requirements, fluctuations in raw material prices, and dependence on third-party distribution channels remain important operational challenges for the business. However, investors continue to monitor the IPO closely because of the overall positive outlook for India’s pharmaceutical and healthcare industries.
The IPO comes during a period of strong activity in India’s SME primary market, where pharmaceutical, food processing, textiles, and restaurant-sector companies are witnessing increasing retail investor participation. Market analysts believe healthcare-focused SME offerings may continue to attract attention due to long-term sector growth opportunities and rising healthcare spending across India.